HGWM
NBIX icon

Harvest Group Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Harvest Group Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11
Closed -$1.31K – 197
2022
Q4 		$1.31K Buy
11
+5
+83% +$586 ﹤0.01% 137
2022
Q3 		$1K Buy
+6
New +$609 ﹤0.01% 151
2022
Q1 		– Sell
-12
Closed -$1K – 153
2021
Q4 		$1K Buy
+12
New +$1.1K ﹤0.01% 101

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Harvest Group Wealth Management's NBIX Position: Q1 2023 in Review

Harvest Group Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 11 shares — an estimated $1.31K sold.

Harvest Group Wealth Management first reported a position in NBIX in Q4 2021 and held it in 3 quarters. The position peaked at $1.31K in Q4 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • Harvest Group Wealth Management reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
  • Harvest Group Wealth Management sold 11 Neurocrine Biosciences shares in Q1 2023, an estimated $1.31K.
  • Harvest Group Wealth Management first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 3 quarters.
  • Harvest Group Wealth Management's Neurocrine Biosciences position peaked at $1.31K in Q4 2022.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Harvest Group Wealth Management's 13F filing for Q1 2023, filed 28 Apr 2023.